Cargando…

Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma

T cell immunoglobulin and ITIM domain (TIGIT) is a recently identified T cell coinhibitory receptor. Studies have shown that TIGIT is expressed in colon adenocarcinoma, uterine corpus endometrioid carcinoma, breast carcinoma and kidney renal clear cell carcinoma. However, the role of the TIGIT/human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Xiangguo, Liu, Juanxi, Cui, Jianjian, Ma, Bin, Zhou, Qiunan, Yang, Xiaojuan, Lu, Zhenhui, Du, Yong, Su, Chunxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755146/ https://www.ncbi.nlm.nih.gov/pubmed/31485637 http://dx.doi.org/10.3892/mmr.2019.10641

Ejemplares similares

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
por: Ozmadenci, Duygu, et al.
Publicado: (2022)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer
por: Liu, Lu, et al.
Publicado: (2022)

CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
por: Matsuo, Tomohei, et al.
Publicado: (2022)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

Elevated expression of TIGIT on CD3(+)CD4(+) T cells correlates with disease activity in systemic lupus erythematosus
por: Luo, Qing, et al.
Publicado: (2017)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myeloma
por: Liu, Zhao‐Yun, et al.
Publicado: (2022)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells
por: Yasutomi, Motoko, et al.
Publicado: (2022)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma
por: Jin, An‐Li, et al.
Publicado: (2022)

TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma
por: Ge, Zhouhong, et al.
Publicado: (2021)

Analysis of the Characteristics of TIGIT-Expressing CD3(−)CD56(+)NK Cells in Controlling Different Stages of HIV-1 Infection
por: Zhang, Xin, et al.
Publicado: (2021)

Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis
por: Li, Wenli, et al.
Publicado: (2021)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

TIGIT as a Novel Prognostic Marker for Immune Infiltration in Invasive Breast Cancer
por: Guo, Chenming, et al.
Publicado: (2023)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism
por: Shao, Qi, et al.
Publicado: (2021)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

The IL-27 receptor regulates TIGIT on memory CD4(+) T cells during sepsis
por: Morrow, Kristen N., et al.
Publicado: (2021)

Co-Expression of TIGIT and Helios Marks Immunosenescent CD8(+) T Cells During Aging
por: Pieren, Daan K. J., et al.
Publicado: (2022)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features
por: Ribeiro, Osmar Damasceno, et al.
Publicado: (2016)

Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma
por: Liu, Fangkun, et al.
Publicado: (2019)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ta86nvclf3m36c3rhbgef3on8